Small molecule inhibitors targeting NF-κB signaling have shown promise in managing inflammatory bone conditions such as periodontitis and rheumatoid arthritis.233–235 These compounds primarily act by inhibiting key kinases involved in NF-κB activation, including IKKβ and NIK. This evidence concerns the gene NFKB1 and rheumatoid arthritis.